Local Officials Tour AstraZeneca Newark, Del. Supply Site
Every day, AstraZeneca works hard to improve health in communities throughout the U.S., primarily through the discovery, development and commercialization of prescription medicines that are used by millions of patients worldwide. The company’s supply chain is a critical component to this mission, and ultimately enables us to ensure the right amount of product is delivered to the right place at the right time for our patients.
Delaware Governor Jack Markell and representatives of the federal congressional delegation recently visited AstraZeneca’s Newark, Del. supply site for a tour, and to learn more about the investments that the company is making to modernize the facility over the next five years.
AstraZeneca’s Newark, Del. facility is a key strategic site in the company’s global supply chain. The site is one of three distribution sites in the U.S., and one of the company’s 25 production facilities in 17 countries worldwide. The facility provides primary and secondary packaging capability and handles the vast majority of packing for the North American market. It also provides formulation capabilities for global markets.
AstraZeneca plans to invest nearly $100 million to modernize the facility, create a state-of-the-art formulation center and centralize packaging operations at this location. The enhancements will help optimize the space and productivity, improve workflow and best position the site for future success. The project will also aid the company in its continued efforts to increase efficiency and effectiveness in its operations.